Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

J S Frenel,J W Kim, N Aryal,R Asher, D Berton,L Vidal,P Pautier, J A Ledermann, R T Penson,A M Oza,J Korach,T Huzarski,S Pignata,N Colombo, T W Park-Simon, K Tamura, G S Sonke, A E Freimund, C K Lee,E Pujade-Lauraine

Annals of oncology : official journal of the European Society for Medical Oncology（2022）

引用 37|浏览16

暂无评分

摘要

Following progression from maintenance olaparib in the recurrent setting, the efficacy of platinum-based subsequent chemotherapy seems to be reduced in BRCA1/2-mutated patients with PSROC compared to patients not previously receiving poly (ADP-ribose) polymerase inhibitors (PARPi). The optimal strategy for patients who relapse after PARPi is an area of ongoing research.

查看译文

关键词

BRCA mutation,PARP inhibitor resistance,relapsing ovarian cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要